Intervention Protocol

Piribedil for levodopa-induced complications in Parkinson's disease

  1. Dulce Neutel2,
  2. Joaquim Ferreira1,*,
  3. Miguel M Coelho1,
  4. Mário Miguel Rosa3,
  5. Olivier Rascol4,
  6. Cristina Sampaio1

Editorial Group: Cochrane Movement Disorders Group

Published Online: 18 JUL 2007

DOI: 10.1002/14651858.CD006707


How to Cite

Neutel D, Ferreira J, Coelho MM, Rosa MM, Rascol O, Sampaio C. Piribedil for levodopa-induced complications in Parkinson's disease (Protocol). Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD006707. DOI: 10.1002/14651858.CD006707.

Author Information

  1. 1

    Faculdade de Medicina de Lisboa, Laboratório de Farmacologia Clínica e Terapêutica, Lisboa, Portugal

  2. 2

    Lisboa, Portugal

  3. 3

    Faculdade de Medicina de Lisboa, Centro de Estudos Egas Moniz, Lisboa, Portugal

  4. 4

    Faculté de Médecine, Pharmacologie Clinique, Toulouse, France

*Joaquim Ferreira, Laboratório de Farmacologia Clínica e Terapêutica, Faculdade de Medicina de Lisboa, Hospital de Santa Maria, Av. Prof. Egas Moniz, Lisboa, 1649-028, Portugal. movementdisord@fm.ul.pt.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 18 JUL 2007

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To evaluate the effectiveness and safety of adjuvant piribedil therapy versus placebo in patients with Parkinson's disease, already established on levodopa and suffering from motor complications.